Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Statement on Gilead’s Announcement of PrEP Donation

Gilead’s donation is an acknowledgment that there is a huge issue with PrEP access in America, as in many parts of the world. We welcome this indication that the company grasps the gravity of the situation. However, we urgently need a lower price for all. It’s disappointing that even this small step has taken so long.

Published
14 May 2019
From
AVAC
A Million Americans Need This Drug. Trump’s Deal Won’t Help Enough of Them.

A donation of H.I.V.-prevention drugs from the pharmaceutical giant Gilead could benefit shareholders more than patients.

Published
14 May 2019
From
The New York Times (editorial)
Generics price-fixing lawsuit focuses on Teva's role as catalyst

The lawsuit focuses closely on the practices of Teva, claiming that an "overarching conspiracy" characterized as an "agreed-upon code that each competitor is entitled to its 'fair share' of the market, whether that market is a particular generic drug, or a number of generic drugs." It documents 12 such arrangements between Teva and other generic companies covering 41 drugs, ranging from cholesterol-lowering drug fenofibrate to copycat versions of the HIV drug Combivir (lamivudine/zidovudine).

Published
14 May 2019
From
Bio Pharma Dive
Five Reasons the Gilead Giveaway is a Steaming Pile of Truvada

Gilead is engaged in a brilliantly self-serving marketing ploy and dressing it up like charity.

Published
12 May 2019
From
My Fabulous Disease
Teva and Other Generic Drugmakers Inflated Prices Up to 1,000%, State Prosecutors Say

Leading drug companies including Teva, Pfizer, Novartis and Mylan conspired to inflate the prices of generic drugs by as much as 1,000 percent, according to a far-reaching lawsuit filed on Friday by 44 states.

Published
12 May 2019
From
New York Times
Generic PrEP to Arrive in September 2020, but Will Big Savings Follow?

Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.

Published
10 May 2019
From
Poz
Gilead Will Donate Truvada to U.S. for H.I.V. Prevention

Officials at the Department of Health and Human Services said the donation came about “as a result of discussions between the Trump administration and Gilead.” Critics said it would not be enough to end the AIDS epidemic and questioned the company’s motives.

Published
10 May 2019
From
The New York Times
Rapid adoption of generic HIV drugs could save NHS £7 billion by 2033

Prescription of generic versions of antiretroviral drugs for treatment and pre-exposure prophylaxis (PrEP) as soon as they come off patent would save the NHS £7 billion between

Published
10 May 2019
By
Keith Alcorn
Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency

A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said.

Published
07 May 2019
From
Health Policy Watch
Gilead Sciences Returns to Growth in the First Quarter

The biotech delivered solid growth in the first quarter on both the top and bottom lines, thanks to strong sales for HIV drug Biktarvy and some good news for its HCV franchise.

Published
03 May 2019
From
Motley Fool

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.